Control group | PSG group | |
Subjects | 30 | 30 |
Age years | 60±9 | 63±12 |
Male/female | 23/7 | 20/10 |
BMI kg·m−2 | 29.5±11.5 | 27.3±6.6 |
Comorbidities | 1.0±1.4 | 1.37±1.4 |
Diagnosis | ||
MND | 18 | 22 |
ALSFRS-R score | 29.3±7 | 28.0±7 |
Bulbar (ALSFRS) score | 8.7±3 | 7.1±4 |
Riluzole at enrolment % | 56 | 73 |
NMD | 7 | 6 |
RTD | 0 | 2 |
OHS | 3 | 0 |
COPD/OSA | 2 | 0 |
FVC % pred | 55±14 | 54±15 |
MIP cmH2O | 30 (23–54) | 28 (22–33) |
Daytime PaCO2 mmHg | 43 (39–48) | 45 (38–51) |
Previous CPAP# % | 36.7 | 20.0 |
Data are presented as n, mean±sd or median (interquartile range). BMI: body mass index; MND: motor neuron disease; ALSFRS: Amyotrophic Lateral Sclerosis Functional Rating Scale; NMD: neuromuscular disorder; RTD: restrictive thoracic disorder; OHS: obesity hypoventilation syndrome; COPD/OSA: chronic obstructive pulmonary disease with obstructive sleep apnoea; FVC: forced vital capacity; MIP: maximum inspiratory pressure; PaCO2: arterial carbon dioxide tension; CPAP: continuous positive airway pressure. #: CPAP previously prescribed, used or evaluated in a laboratory or inpatient setting.